PDCD1 and lung cancer: An overview of current clinical experimental results, including KEYNOTE-189, KEYNOTE-407, IMPOWER133, CASPIAN, and others (3–6), demonstrated that PD-1/PD-L1 inhibitors plus chemotherapy are gradually emerging as a novel therapeutic paradigm for advanced lung cancer patients.